ERBB2 and breast cancer: Small interference RNA (siRNA) directed VIPR1 silencing suppressed angiogenesis by inhibiting VIP effects on both VEGF secretion and EGFR/HER2 transactivation, which implied the use of VIPR1 antagonists for breast cancer treatment 29, 30.